Ceribell Inc. has announced a significant development in its ongoing collaboration with The Board of Trustees of the Leland Stanford Junior University. The company has exercised an option to extend its exclusive license for certain portable brain wave activity devices, under the Stanford Agreement. This decision, formalized in Amendment No. 4, allows Ceribell to maintain exclusivity through the expiration of the last-to-expire licensed patent. To secure this extension, Ceribell has agreed to pay an option exercise fee of $250,000. This strategic move reinforces Ceribell's commitment to advancing its innovative medical technologies in partnership with Stanford.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。